The Durham, NC-based drug developer's stock soared on its first day of trading, with an initial price of $14 per share that shot up 34% to $18.79 per share by the end of the day.
Two biotech players have offered price ranges for their hoped-for initial public offerings. Chimerix aims to sell 6.1 million shares for between $13 and $15 per share, and Omthera has priced its IPO shares in the $12 to $14 range.
As the biotech advances its lead antiviral drug to Phase III development, Chimerix has tapped a veteran of one of the most high-profile pharma R&D programs in the world.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin ( email | Twitter ) and we will feature it...
Research Triangle Park, NC-based Chimerix has inked its first big partnership, reaping a $17.5 million upfront payment and a promise of up to $151 million more from Merck, which gains rights to a mid-stage antiviral--CMX157--which has prospects as a new addition to future HIV cocktails.
With two antiviral drug candidates in the clinic, Durham, NC-based Chimerix has raised $45 million in a Series F round of financing. New Leaf Venture Partners led the round. The firm was joined by
SIGA Technologies says it has been selected to deliver a smallpox antiviral drug to the nation's biodefense stockpile, landing a contract which is worth $500 million at the base level and zooms all
With an experimental antiviral in mid-stage clinical trials, Research Triangle Park, NC-based Chimerix has raised $16.1 million from a Series E. Canaan Partners, Alta Partners, Sanderling Ventures
Scientists at Saint Louis University School of Medicine say that an experimental therapy being tested by Durham, NC-based Chimerix may become the first candidate for human trials for adenovirus.